COMPETE-Trial

A prospective, randomised, Controlled, Open-label, Multicentre phase III study to evaluate efficacy and safety of Peptide Receptor Radionuclide Therapy (PRRT) with 177Lu-Edotreotide compared to targeted molecular therapy with Everolimus in patients with inoperable, progressive, somatostatin receptor-positive (SSTR pos.), neuroendocrine tumours of gastroenteric or pancreatic origin (GEP-NET). 177Lu-edotreotide vs. everolimus in GEP-NET (COMPETE-Trial)

III

interventionell

International

177Lu-edotreotide

Status: In Rekrutierung

Zeitraum

2017

2022

Zentren

54

54

Keine Zentren gesucht

Patienten

300

297

28.03.2022

Klinische Settings

palliativ

Beteiligte

AIO-Arbeitsgruppen

Sponsor

ITM Solucin GmbH

Identifier

AIO-NET-0417/ass

AIO-NET-0417/ass

2016-001897-13

Kontakt

Leitung

Prof. Dr. Wolfgang Weber

Ansprechpartner*in

Dr. Nicolas Schneider / Amanda Rotger, MD
E-Mail info-solucin@itm-radiopharma.com